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A B S T R A C T
Objective: The objective of this study was to determine the cost-effectiveness of using
transdermal nitroglycerin (GTN) for cases of preterm labor.
Methods: The study included 153 women with clinical preterm labor, who were randomly
allocated to either a GTN or placebo arm. All randomized cases were included in the final
economic analysis. Differences between the two arms in gestational age at delivery, neona-
tal intensive care unit (NICU) admission, length of NICU stay, and NICU cost were assessed.
Costs for non-NICU cases were calculated using Ottawa Hospital data through the Ontario
Case Costing Initiative (OCCI). Cost-effectiveness and sensitivity analyses using a hospital
perspective were both conducted.
Results: In the 153 randomized cases, 55 babies were admitted to NICU (GTN 24; placebo
31).We found no significant differences between the two arms in gestational age at delivery,
NICU admission rate (32.4% vs. 39.2%), NICU length of stay (42.7 days vs. 52.8 days), or NICU
cost (CAN $34,306 vs. CAN $44,326). Overall, (based on all randomized cases) the cost-effec-
tiveness analyses showed that the GTN arm was the dominant strategy, with both lower
cost (CAN $13,397 vs. CAN $18,427) and higher NICU admission avoided rate (67.6% vs.
60.8%) compared to the placebo arm. This dominance persisted in all sensitivity analyses.
Conclusion: The use of GTN patch for preterm labor could reduce NICU costs, while im-
proving important neonatal outcomes.
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Preterm birth is the leading cause of perinatal morbidity and
mortality and is a major public health problem in terms of
long-term disability and health care costs in industrialized
countries [1]. From 2006 to 2007 in Canada, approximately
8.1% of pregnancies were delivered preterm (37 completed
weeks of gestation). Among them, about 1% of pregnancies
were delivered before 32 weeks and 0.3% before 28 weeks [2].
n extremely preterm births (28 weeks of gestation), the oc-
urrence of severe neonatal complications, such as chronic
ung disease, necrotizing enterocolitis (NEC), intraventricular
emorrhage (IVH), and periventricular leukomalacia (PVL), is
uite common. These conditions often require extensive use
f neonatal intensive care units (NICUs). Medical and techno-
ogical advances in the care of premature infants, although
ubstantially increasing the chance of survival for these in-
ants, have imposed high costs to the health care system [1].
In the United States, the total annual expenditure for pre-
aturity has been estimated recently to be approximately US
26 billion [3]. Based on data released by the Canadian Insti-
ute for Health Information (CIHI) in 2006, hospitals in Canada
excluding those in Quebec and rural Manitoba) spent roughly
AN $295 million on neonatal care, and the burden on society
ould be even greater if the consequent long-term costs were
aken into account [4]. It is estimated that the Canadian health
ystem spends almost CAN $2 billion a year to take care of
remature babies and their medical complications.
Most available tocolytic agents used for preterm labor,
uch as adrenergic receptor agonists (e.g., ritodrine), magne-
ium sulfate (e.g., MgSO4), calcium channel blockers (e.g., ni-
fedipine), and oxytocin antagonists (e.g., atosiban), had no ef-
fect (or even caused adverse effects in some cases) on
neonatal outcomes [5–10]. In contrast, recent studies in hu-
mans and animals showed that transdermal nitroglycerin
(GTN) could reduce serious maternal and fetal complications
[11]. As demonstrated in our trial, the use of GTN in preterm
labor prolongs gestation and reduces the risk of severe neona-
tal outcomes [2].The improved outcomesmay be attributed to
a prolongation of gestation, allowing sufficient time for prena-
tal steroid administration and also the potential nontocolytic
effect of GTN, such as a direct effect on uterine blood flow or
placenta [12].
The potential for substantial societal and family costs as-
sociated with both preterm birth and having a sick baby or
child suggests that treatment with GTN may result in major
cost saving and longer-term health benefits for these babies.
The purpose of the current study was to determine the cost-
effectiveness of GTN use for preterm labor from a hospital
perspective.
Methods
Overview
Themulticenter, randomized Canadian Preterm Labour Nitro-
glycerin Trial was conducted from May 2001 to July 2004. Inthis trial, 153 women who were clinically in preterm labor
between 24 and 32 weeks were randomly allocated to either a
GTN or placebo patch group. A total of 14 sites participated in
this study, with Kingston General Hospital acting as the lead
hospital and Ottawa Hospital providing data management
services. Subjects were stratified by center and gestational
age. The trial demonstrated that there is a significant reduc-
tion in neonatal morbidity and mortality by using GTN for
preterm labor. Details of the trial have been reported previ-
ously in a separate article [2].
Economic study design
The economic evaluationwas undertaken ancillary to the pre-
viously completed GTN trial and used patient-level data from
the GTN study database. NICU admission, NICU length of stay,
and NICU cost were calculated after stratification by gestational
age in the two arms. NICU costs were estimated individually by
using the Ottawa Hospital NICU costs by days of stay and birth
weight groupings data in fiscal year 2003–2004 (see Appendix A
and Appendix B at doi:10.1016/j.jval.2010.10.019). Those who
were not admitted to the NICU had costs calculated using
data from the OCCI for Ottawa Hospital during the same
time period using the appropriate Case Mix Groups (CMGs)
(see Appendix C at doi:10.1016/j.jval.2010.10.019). In this
study, both the cost-effectiveness analysis and sensitivity
analysis were conducted including all randomized cases. The
primary outcome for the economic analysis was the cost per
percent reduction in the number of neonates admitted to the
NICU by employing a hospital perspective. The intent was to
determine the cost associated with a reduction in the number
of cases admitted to the NICU, rather than the cost per num-
ber of days avoided in the NICU.
Cost-effectiveness analysis
The hospital costs consisted of three elements: GTN costs,
general hospital costs, and NICU costs. GTN costs included
drug cost (about CAN $1) and administration cost (about CAN
$50), which were provided by physicians in Ottawa Hospital.
Administration costs included both the cost of a physician
consultation and nursing time. In each arm, the neonatal hos-
pital NICU costs were estimated by NICU cost by days of stay
data reported by Ottawa Hospital. The NICU costs were calcu-
lated by adding the average cost for each day, rather than
taking the average cost over the length of stay andmultiplying
by the number of days. This method ensured that we did not
overstate any cost changes related to length of stay. We chose
thismethod becausemost NICU stays have higher initial daily
costs and then typically diminish over time as the neonate’s
condition improves. Costs for cases that did not require NICU
admissionwere figured using the OCCI data fromOttawaHos-
pital for the period 2003–2004 and included those who deliv-
ered at full term (37 weeks). These costs were calculated
with CMG codes by neonate weight, excluding those with se-
vere complications, as these cases would likely be admitted to
the NICU. Cost codes used for preterm neonates less than 28
weeks (626) represented neonates weighing between 750 and
1000 grams. Cost codes used for preterm neonates between 28
acomp
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tween 1000 and 2000 grams. Cost codes for preterm neonates
between 32 and 37 weeks (636, 637, 638, 639, 640) represented
neonates weighing between 2000 and 2500 grams. Cost codes
for full-term neonates (644, 645, 646, 647, 648) represented ne-
onates weighingmore than 2500 grams. It is important to note
that these costs represent the direct hospital costs only, and
do not include costs that occur outside the hospital nor the
impact on indirect costs. Hence, hospital cost changes in this
analysis are likely a conservative estimate of the true costs
associated with these procedures.
The effectivenessmeasurement used in this cost-effective-
ness analysiswas defined as theNICU admission avoided rate.
The NICU admission rates were calculated first in both arms,
and then the NICU admission avoided rates were measured.
Next, cost per percentage of NICU admission avoided was as-
sessed in both arms. We then checked for dominance, and, if
necessary, we calculated the incremental cost-effectiveness
ratio (ICER) with the change in total costs as the numerator
and the change in NICU admission avoided rates as the de-
nominator. In Tables 1, the term “dominant” refers to a ther-
py with lower costs and improved effects.
Sensitivity analysis
Sensitivity analysis was performed for variations in hospital
costs (including NICU costs) and GTN efficacy. We used the
95% confidence interval (CI) for hospital and NICU costs to
determine upper and lower limits in our sensitivity analysis,
according to the data reported by OCCI and CIHI [4]. We used a
10% variation in GTN efficacy in the sensitivity analysis, as
the lower bound reflects only a very modest (1%) improve-
ment in NICU avoidance. We also ran a worst-case scenario
Table 1 – Cost-effectiveness analysis (per neonate).
Descriptor GTN
n Unit cost
(CAN $)
Total
(CAN $
NICU, 370 weeks 24 34,357 824,568
Preterm 280 weeks, no NICU* 0 0 1
Preterm 281–320 weeks, no NICU† 5 17,641 88,205
Preterm 321–370 weeks, no NICU‡ 10 3,972 39,720
Full term§ 35 1,110 38,850
All patients 74 991,343
Cost per case ($) 13,396.5
Incremental cost/case ($) 5,030.3
Effectiveness (percent avoiding
NICU)
67.5
Incremental effectiveness 6.8
Dominant YES
$, CAN $; 0, 0 days; 1, 1 day; NA, not applicable.
* The one case was a stillbirth. We estimated the cost at CAN $1000
† OCCI data for Ottawa Hospital 2003–2004, 1000–2000 g, excludes m
‡ OCCI data for Ottawa Hospital 2003–2004, 2000–2500 g, excludes m
§ OCCI data for Ottawa Hospital 2003–2004, 2500 g, excludes major(higher hospital costs, lower GTN efficacy) in this analysis.Results
In the original trial, 74women allocated to the GTNarmand 79
women allocated to the placebo armwere included in the final
analysis. In the GTN arm, there were 39 womenwho delivered
preterm; in the placebo arm, there were 38 women who deliv-
ered preterm. In the GTN arm, 24 newborns were admitted to
the NICU; in the placebo arm, 31 newborns were admitted to
the NICU. In total, 3 babies enrolled in the placebo arm died
during the trial. One was stillborn and the other two died after
admission to NICU. In addition, there were three cases miss-
ing the neonatal discharge dates in the placebo arm.
NICU admission, length of stay, and costs
A comparison of the rates of NICU admission, average NICU
length of stay, and average NICU cost between the two study
arms are presented in Table 2. In all randomized cases, there
was no difference in gestational age at delivery (P  0.068)
between the two arms. Although the NICU admission rates
(32.4% vs. 39.2%), the averageNICU length of stay (42.7 days vs.
52.8 days), and the average NICU cost (CAN $34,306 vs. CAN
$44,326) in the GTN arm were all lower than those of the pla-
cebo arm, statistically, the differences between the two arms
were not significant. Meanwhile, there were no statistically
significant differences in NICU admission rates, average NICU
length of stay, and average NICU cost by gestational age (280
weeks, 281 to 320 weeks, 321 to 370 weeks, and 371 weeks).
Cost-effectiveness
The average NICU cost for a preterm infant in the GTN arm
was estimated to be CAN $34,306; that of the placebo armwas
estimated to be CAN $44,326. Then average hospital neonatal
Placebo
n Unit cost
(CAN $)
Total
(CAN $)
CMG codes
(Ottawa Hospital)
31 44,326 1,374,106 NA
1,000 1,000 626
1 17,590 17,590 628, 632
5 3,921 19,605 636, 637, 638, 639, 640
41 1,059 43,419 644, 645, 646, 647, 648
79 1,455,720
18,426.84
60.76%
e base case.
omplications (NICU stay for these cases).
omplications (NICU stay for these cases).
lications (NICU stay for these cases).)
3
1
7%
1%
for th
ajor c
ajor ccost for a preterm infant in the GTN arm was CAN $34,357
w
6
w
term
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CAN $44,326 (Table 1). For all randomized cases (with or
without NICU cost), the average cost from a hospital per-
spective was $13,397 for the GTN arm and $18,427 for the
placebo arm.
The pretermbirthNICU admission rate in theGTNarmwas
61.5% (24 of 39); that of the placebo armwas 81.6% (31 of 38). In
the overall sample including all randomized cases, the num-
ber of NICU admissions avoided was 67.6% for the GTN arm
and 60.8% for the placebo arm.
Table 2 – Preterm birth outcomes in two arms.
GTN (
Gestational age (weeksd) at delivery
280 7
281 to 320 17
321 to 370 15
371 35
NICU admission (%) 24
280 weeks 7
281 to 320 weeks 12
321 to 370 weeks 5
Neonatal death 0
Average NICU length of stay (days)* 42.7
280 weeks 72.9
281 to 320 weeks 39.0
321 to 370 weeks 9.2
Average full-term length of stay (days) n
371 weeks 2.2
Average NICU cost (CAN $)* 34,306
280 weeks 66,079
281 to 320 weeks 27,493
321 to 370 weeks 6,174
Average full-term cost (CAN $) 371 weeks 1,112
d, days; 0, 0 days; 1, 1 day; $, CAN $; NA, not applicable.
* Three cases were missing the discharge dates in the placebo arm.
† OCCI length of stay and costing data for the period 2003–2004 for O
‡ GTN administration costs of CAN $51 added to average cost of full-
Table 3 – One-way and multiway sensitivity analysis (per
Average
cost
Incremental
cost
NICU/hospital cost increase
(upper CI)
Placebo $18,599
GTN $13,866 $4,733
NICU/hospital cost
decrease (lower CI)
Placebo $18,267
GTN $12,926 $5,341
GTN efficacy increase (10%)
Placebo $18,427
GTN $13,397 $5,030
GTN efficacy decrease (10%)
Placebo $18,427
GTN $13,397 $5,030
Worst case
Placebo $18,599
GTN $13,866 $4,733$, CAN $; NA, not applicable.As indicated in Table 1, the incremental cost per case in the
GTN arm was negative (cost saving), with a value of $5,030,
hereas the incremental effectiveness of the GTN arm was
.81% higher than the placebo arm. Therefore, the GTN therapy
as the dominant strategy when compared to the placebo arm.
Sensitivity analysis
We conducted a series of one-way sensitivity analyses based on
costs and efficacy, as well as a worst case scenario to determine
74) Placebo (n  79) P value
0.068
16
8
14
41
) 31 ( 39.2) 0.381
15
7
9
3 0.332
4) 52.8 (n  28) 0.503
) 82.9 (n  12) 0.175
2) 43.3 (n  7) 0.637
) 19.9 (n  9) 0.109
n  41
I†) 2.2 (OCCI†) NA
4) 44,326 (n  28) 0.303
) 78,890 (n  12) 0.446
2) 27,417 (n  7) 0.993
) 11,390 (n  9) 0.121
I†,‡) 1,061 (OCCI†) NA
a Hospital.
birth.
ate).
ffectiveness Incremental
effectiveness
Dominant ICER
60.76%
67.57% 6.81% YES NA
60.76%
67.57% 6.81% YES NA
60.76%
74.32% 13.56% YES NA
60.76%
61.43% 0.67% YES NA
60.76%
61.43% 0.67% YES NAn 
( 32.4
(n  2
(n  7
(n  1
(n  5
 35
(OCC
(n  2
(n  7
(n  1
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(OCC
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244 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 2 4 0 – 2 4 6whether dominance prevailed. As illustrated in Table 3, we var-
ied NICU costs and noted that our outcome was not sensitive to
changes in these costs. For theGTNefficacy, variation in efficacy
within plausible ranges (10%) still indicated that GTN was the
ominant strategy (Fig. 1), and even the worst case scenario il-
ustrateddominance.The results fromthese sensitivityanalyses
uggest that theoutcomewas robust, as they all showed that the
TN armwas the dominant strategy.
Discussion
Given the high societal and health costs associated with preterm
infants and the associated neonatal morbidity, the use of GTN in
preterm laborhas thepotential to reduce costs and improve longer
termhealth.
To our knowledge, the economic impact of using GTN
patches as a solution for delaying preterm labor has not been
studied. There are, however, a number of studies on using other
medications to delay preterm labor with some discussion of the
resulting cost implications [13–16]. According to CIHI reports,
hospital costs increased substantially and linearly with a de-
crease in gestational age [17]. For example, the hospital cost for
eachextremelypretermbirth (28weeksofgestation) inCanada
s CAN $84,235, whichwas 33 times higher than those of infants
orn at 36weeks of gestation [17]. The average hospital costs for
Fig. 1 – GTN costreterm infants were nine times higher than for term infants t17]. Babies born pretermwere at increased risk ofmortality and
orbidity andmost of themwere admitted to a Canadian NICU
nd remained there until discharge [4]. NICU care is one of the
ost expensive typesofhospital care. Because thehighcosts are
ssociated with the number of days spent in the neonatal NICU,
ignificant savings in cost of neonatal care could be achieved by
hortening the NICU stay [18].
In the cost-effectiveness analysis, the total costs per case in
he GTN arm were lower than those in the placebo arm, which
as driven largely by the reductions in NICU length of stay.
eanwhile, the effectiveness in the GTN arm was higher than
hat of the placebo arm, so the incremental cost effectiveness
nalysis of GTNuse produced a dominant scenario.Weused the
5%CI for hospital andNICUcosts to determineupper and lower
imits of costs in our sensitivity analysis, according to the data
eported by OCCI and CIHI. In terms of GTN efficacy, we used a
10% variation in the sensitivity analysis (as the lower bound
eflects only a very modest improvement in NICU avoidance)
nd still found that the GTN arm was dominant. Therefore, the
se of GTN patch for preterm labor could dramatically reduce
he cost of hospital care, while improving important neonatal
utcomes.
Our study has several limitations. The full cost for each
aby in participation centers in this trial was not captured.
nly hospital costs were estimated by using the Ottawa Hos-
ital CMG and specific NICU costs by days of stay data; hence,
ctiveness plane.-effehis outcome is likely a conservative estimate of GTN benefit.
245V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 2 4 0 – 2 4 6Neonatal care costs of preterm labor could be divided into
several categories, and the cost estimating methods could be
more comprehensive by including both the direct and indirect
costs. Although the hospital NICU cost was the most impor-
tant component of neonatal care, parents of preterm new-
borns, for example, may require support from social service
departments upon their discharges from hospitals. They may
have to give up some economic activities (paid or unpaid
work) in order to spend time with the preterm newborns, and
costs of transport to and from the hospital may be incurred
[19,20]. In addition, economic impact of a preterm birth may
last for many years. Preterm infants may, for example, have
additional health care needs that lead to hospital readmission
or visits to general practitioners and other health care provid-
ers. Different educational needs and additional care require-
ments for daily lifemayhave to bemet in the long term [21,22].
It is recommended that social services, transport costs, parent
unpaid work, long-term disability costs, additional education,
and additional care need to be included in the assessment for
future studies. The choice of change in percent requiringNICU
admission is not a commonly used outcomemeasure, but the
literature in this field is limited. Jakovljevic et al. [13] used the
cost per week of pregnancy prolongation, and Obido et al. [23]
used the cost per preterm delivery less than 37 weeks pre-
vented. We believe that our measure is similar but more
meaningful because themain implication in delaying delivery
is to avoid complications and the need for protracted NICU
stays. We also suspect that the use of either of these two au-
thors’ outcome measures would also demonstrate domi-
nance. Because of the small sample size of the original trial, no
significant differences in NICU admission rate, average NICU
stay, and average NICU cost between the two arms were
found. Hence, the bias caused by small sample size cannot be
excluded.
Despite the limitations, we found in our study that the use
of GTN patch for preterm labor was the dominant strategy,
with both lower costs and higher NICU admission avoided
rates compared to the placebo arm. The NICU cost reduction
was driven by the shortening of NICU stay and the improved
neonatal outcomes. Because the cost of using GTN patch in a
prenatal care setting is a relatively small investment, policies
should be developed so that using the GTN patch for preterm
labor is done more routinely.
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